Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice

Reproductive Toxicology

Volumn 24, Issue 3-4, 2007, Pages 310-316

  Fukushima, Ryou ^a   Kanamori, Susumu ^a   Hirashiba, Masahiro ^a   Hishikawa, Atsuko ^a   Muranaka, Ri ich ^a   Kaneto, Masako ^a   Nakamura, Kazuichi ^a   Kato, Ikuo ^a  

^a Developmental Research Laboratories   (Japan)

Author keywords

Dihydroorotate dehydrogenase; Leflunomide; Mouse; Protein tyrosine kinase; Pyrimidine; Teratogenicity

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE NUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLEFT PALATE; CONTROLLED STUDY; CRANIOFACIAL MALFORMATION; ENZYME ACTIVITY; FEMALE; FETAL WELL BEING; FETUS; HEART VENTRICLE SEPTUM DEFECT; LIMB MALFORMATION; MALE; MOUSE; NEURAL TUBE DEFECT; NEWBORN; NONHUMAN; NUCLEOTIDE METABOLISM; PATENT DUCTUS ARTERIOSUS; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; AORTA; BONE AND BONES; CRANIOFACIAL ABNORMALITIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO LOSS; FEMALE; FETAL RESORPTION; HEART DEFECTS, CONGENITAL; ISOXAZOLES; MALE; MICE; PREGNANCY; TERATOGENS;

MUS;

EID: 35548953841     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2007.05.006     Document Type: Article

References (19)

1. Brent R.L. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63 (2001) 106-112
2. Prakash A., and Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 58 (1999) 1137-1164
3. Huang M., Wang Y., Collins M., and Mitchell B.S. Graves LM. A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. Mol Pharmacol 62 (2002) 463-472
4. Pinschewer D.D., Ochsenbein A.F., Fehr T., and Zinkernagel R.M. Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine. Transplantation 72 (2001) 712-719
5. Silva H.T., Cao W., Shorthouse R., and Morris R.E. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant Proc 28 (1996) 3082-3084
6. Siemasko K., Chong A.S., Jack H.M., Gong H., Williams J.W., and Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 160 (1998) 1581-1588
7. Elder R.T., Xu X., Williams J.W., Gong H., Finnegan A., and Chong A.S. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 159 (1997) 22-27
8. Goldenberg M.M. Leflunomide a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther 21 (1999) 1837-1852
9. Waldman W.J., Bickerstaff A., Gordillo G., Orosz K., Knight D.A., and Orosz C.G. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. Transplantation 72 (1993) 1578-1582
10. Mattar T., Kochhar K., Bartlett R., Bremer E.G., and Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS 334 (1993) 161-164
11. Xu X., Williams J.W., Bremer E.G., Finnegan A., and Chong A.S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 270 (1995) 12398-12403
12. Leflunomide Summary Basis for Approval submitted to Japan Ministry of Health, Labor and Welfare (Japanese). Tokyo, Japan: Sanofi-aventis K.K.; 2003.
13. Kuo E.A., Hambleton P.T., Kay D.P., Evans P.L., Matharu S.S., Little E., et al. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3′-methyl-4′-(trifluoromethyl)phenyl] propenamide and related compounds. J Med Chem 39 (1996) 4608-4621
14. Arava Clinical Pharmacology and Biopharmaceutics Review(s). World Wide Web site by Food and Drug Administration.
15. ® (mycophenolate mofetil capsules) Complete Product Information. Hoffmann-La Roche Inc. Company World Web Site by Roche.
16. Le Ray C., Coulomb A., Elefant E., Frydman R., and Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103 (2004) 1091-1094
17. Kawai Y., Yoshida A., Nakagawa S., Hama T., and Mayumi T. Effect of bredinin on early embryonic development in mice. Biol Pharm Bull 16 (1993) 133-136
18. Kobarashi Y., Matsumoto K., Hoshino Y., and Hayano K. Teratogenic effects of a new immunosuppressive agent, Bredinin, in the mouse. Teratology 10 Suppl. (1974) 87
19. Okamoto K., Kobayashi Y., Yoshida K., Nozaki Y., Kawai Y., Kawano H., et al. Teratogenic effects of Bredinin, a new immunosuppressive agent, in rats. Congenit Anom (Kyoto) 18 (1978) 227-233